samedan logo
 
 
 
spacer
home > ebr > summer 2021 > the power of our dna – paving the way for precision cancer care
PUBLICATIONS
European Biopharmaceutical Review

The Power of Our DNA – Paving the Way for Precision Cancer Care

Scientific discoveries and advances have led to a greater understanding of the role that our genetic makeup plays in the risk of developing certain cancers, including ovarian cancer, and our potential to respond to specific medicines. Over the past 20 years, precision medicine has become a staple in oncology for the treatment of many cancer types, with patients able to receive medicines specifically tailored to their individual tumour composition and DNA. In the field of ovarian cancer, precision medicines have been a revelation to a once hard to treat disease and have led to a frameshift in both prognosis and quality of life for patients. With ovarian cancer diagnoses expected to rise within the coming years, precision medicines and biomarker testing hold the key to ensuring the best outcomes for these women (1).

By enhancing our underlying understanding of tumour development and the biological processes responsible, we have been able to formulate more optimal disease management and treatment strategies that are based on a patient’s precise tumour/genetic profile leading to improved outcomes and better quality of life. The days of purely providing disease management based on the organ that a tumour is found in are far behind us. Cancer can no longer be treated as a single entity, rather a complex, multifactorial disease for which there cannot be a one-size-fits-all mindset.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Isabelle Ray-Coquard is Professor of Medical Oncology at Claude Bernard University Lyon I, France. She is the Network Director of the national network dedicated to diagnosis and management of rare gynaecological cancer. Her research focuses on the factors that determine medical practices in oncology and rare gynaecology cancer biology. She is President of the GINECO group and a member of several professional groups, including the American Society of Clinical Oncology, European Organisation for Research and Treatment of Cancer, European Society of Medical Oncology, European Society of Gynaecological Oncology, Connective Tissue Oncology Society, and the French Cancer Society.
spacer
Isabelle Ray-Coquard
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Moderna Announces FDA Advisory Committee Unanimously Votes in Support of Emergency Use for a Booster Dose of Moderna’s COVID-19 Vaccine in the U.S.

Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today confirmed that the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) recommended that the FDA grant an Emergency Use Authorization (EUA) for a booster dose of the Moderna COVID-19 vaccine.
More info >>

White Papers

Tightening Your Supply Chain Against Counterfeits

World Courier

As today’s global pharmaceutical supply chain grows increasingly longer and more complex, each link provides added opportunity for counterfeiters. While pending regulatory changes promise to tighten the supply chain with respect to production and distribution entities and new packaging technologies will make the identification of counterfeit products easier, the logistics of global distribution remains a weak link. How can the pharmaceutical shipper ensure the security of the supply chain over thousands of miles and extended periods of time when the product is no longer in his possession?
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement